Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$7.96 0.00 (0.00%) as of 4:30 Wed 9/18


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.51(B)
Last Volume: 1,754,233 Avg Vol: 4,315,920
52 Week Range: $4.13 - $8.69
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  1115
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 183,601 183,601 183,601
Total Buy Value $0 $1,048,338 $1,048,338 $1,048,338
Total People Bought 0 10 10 10
Total Buy Transactions 0 10 10 10
Total Shares Sold 0 11,387 11,387 506,586
Total Sell Value $0 $69,059 $69,059 $6,068,300
Total People Sold 0 2 2 10
Total Sell Transactions 0 2 2 16
End Date 2024-06-23 2024-03-22 2023-09-22 2022-09-22

   
Records found: 755
  Page 22 of 31  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-01-13 4 OE $3.78 $133,151 D/D 35,225 84,839     -
   Sheridan William P SR VP - CMO   •       •      –    2014-01-01 4 D $7.60 $20,786 D/D (2,735) 82,539     -
   Babu Yarlagadda S VP Drug Discovery   •       •      –    2014-01-01 4 D $7.60 $18,255 D/D (2,402) 152,630     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2014-01-01 4 D $7.60 $18,643 D/D (2,453) 49,614     -
   Stonehouse Jon P President & CEO   •       •      –    2014-01-01 4 D $7.60 $65,299 D/D (8,592) 504,360     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2014-01-01 4 D $7.60 $18,643 D/D (2,453) 42,478     -
   Abercrombie George B Director   •       •      –    2013-11-12 4 B $6.19 $18,570 D/D 3,000 6,000 2.81     -
   Baker Bros. Investments, L.p. 10% Owner   –       –       •   2013-08-01 4 B $4.40 $5,000,002 I/I 1,136,364 145,533 1.5     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       –      –    2013-07-26 3 IO $0.00 $0 D/D 0 41,931     -
   Sheridan William P SR VP - CMO   •       •      –    2013-05-28 4 OE $1.20 $19,688 D/D 16,407 82,274     -
   Stonehouse Jon P President & CEO   •       •      –    2013-05-23 4 OE $1.20 $215,520 D/D 179,600 509,952     -
   Abercrombie George B Director   •       •      –    2013-03-05 4 B $1.23 $3,690 D/D 3,000 3,000 2.73     -
   Sheridan William P SR VP - CMO   •       •      –    2013-03-01 4 D $1.19 $2,129 D/D (1,789) 62,867     -
   Babu Yarlagadda S VP Drug Discovery   •       •      –    2013-03-01 4 D $1.19 $2,265 D/D (1,903) 155,032     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2013-03-01 4 D $1.19 $645 D/D (542) 49,322     -
   Stonehouse Jon P President & CEO   •       •      –    2013-03-01 4 D $1.19 $7,101 D/D (5,967) 331,258     -
   Sheridan William P SR VP - CMO   •       •      –    2013-01-31 4 A $1.38 $4,140 D/D 3,000 67,656     -
   Stonehouse Jon P President & CEO   •       •      –    2013-01-31 4 A $1.38 $4,140 D/D 3,000 340,225     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2013-01-31 4 A $1.38 $3,788 D/D 2,745 52,609     -
   Stonehouse Jon P President & CEO   •       •      –    2013-01-01 4/A A $0.00 $0 D/D 62,600 333,319     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2013-01-01 4 A $0.00 $0 D/D 17,000 49,864     -
   Stonehouse Jon P President & CEO   •       •      –    2013-01-01 4 A $0.00 $0 D/D 66,506 337,225     -
   Sheridan William P SR VP - CMO   •       •      –    2013-01-01 4 A $0.00 $0 D/D 17,000 64,656     -
   Babu Yarlagadda S VP Drug Discovery   •       •      –    2013-01-01 4 A $0.00 $0 D/D 17,000 156,935     -
   Jensen Peder Director   •       •      –    2012-12-14 4 B $1.51 $30,200 D/D 20,000 60,000 2.39     -
  755 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 22 of 31
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us